Edition:
United States

Diagnos Inc (ADK.V)

ADK.V on TSX Venture Exchange

0.12CAD
3:58pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.12
Open
$0.12
Day's High
$0.13
Day's Low
$0.11
Volume
2,340,654
Avg. Vol
782,477
52-wk High
$0.17
52-wk Low
$0.04

Latest Key Developments (Source: Significant Developments)

Diagnos Inc announces closing of second tranche of private placement
Tuesday, 1 Sep 2015 04:30pm EDT 

Diagnos Inc:Says further to the closing of the private placement initially announced on July 30, 2015 for gross proceeds of $2,290,000, the Corporation has received the outstanding proceeds of $700,000.The private placement is subject to final receipt of the TSX Venture Exchange approval.  Full Article

DIAGNOS Inc announces licensing deal with Inb al Haythem Center in Algeria
Monday, 4 May 2015 09:30am EDT 

DIAGNOS Inc:Announces licensing deal with Inb al Haythem Center in Algeria.Says it will provide telemedicine software, CARA, and automated retina image interpretation in order to help optimize the clinic's existing retina screening services.  Full Article

Diagnos Inc announces licensing deal with Clinique Hamouche in Algeria
Tuesday, 14 Apr 2015 09:00am EDT 

Diagnos Inc:Announces Licensing Deal With Clinique Hamouche in Algeria.Says it will be providing it's proprietary telemedicine software, CARA, and retina image interpretation to help clinic in adding an additional service for it's patients, retina screening.Preliminary contract is valid for one year with possibility for renewal and expansion.  Full Article

Diagnos Inc announces two year renewal of successful program in UAE
Thursday, 26 Mar 2015 09:47am EDT 

Diagnos Inc:Says renewal of agreement originally announced on March 14, 2012 that has since been renewed and expanded to a total of fourteen mobile screening units.Says value of two year agreement is about C$716,000.  Full Article

Diagnos Inc announces first screening project in Poland with pharmaceutical Company
Wednesday, 18 Mar 2015 12:57pm EDT 

Diagnos Inc:signs contract with a large global pharmaceutical company that markets a leading ophthalmology product indicated for a variety of ophthalmic complications, including those associated with diabetes, for a screening project in Poland.Says this project is in conjunction with the same global pharmaceutical company that DIAGNOS works with around the world, including the UAE and India.According to the International Diabetes Federation, there are over two mln people suffering from diabetes in Poland.Following clinical guidelines, 100 pct of this diabetic population should have their retinas screened yearly, but, currently, only a small proportion of the population is.  Full Article

Diagnos announces contract with a Ophthalmology Pharmaceutical Company in USA
Tuesday, 10 Mar 2015 11:05am EDT 

Diagnos Inc:Says the close of a commercial agreement to provide retina screening services to patients in the United States.Sponsor of the services is a major U.S.-based pharmaceutical company that markets a ophthalmology product indicated for a variety of ophthalmic complications including those associated with diabetes.  Full Article